158 related articles for article (PubMed ID: 24942502)
21. Switch patterns of osteoporosis medication and its impact on persistence among postmenopausal women in the U.K. General Practice Research Database.
Li L; Roddam A; Ferguson S; Feudjo-Tepie M; Taylor A; Jick S
Menopause; 2014 Oct; 21(10):1106-13. PubMed ID: 24569621
[TBL] [Abstract][Full Text] [Related]
22. Long-term persistence with anti-osteoporosis drugs after fracture.
Klop C; Welsing PM; Elders PJ; Overbeek JA; Souverein PC; Burden AM; van Onzenoort HA; Leufkens HG; Bijlsma JW; de Vries F
Osteoporos Int; 2015 Jun; 26(6):1831-40. PubMed ID: 25822104
[TBL] [Abstract][Full Text] [Related]
23. Denosumab utilization among older adults in Ontario: patient characteristics, persistence with therapy, and return to therapy after an extended gap.
Ban JK; Hao BB; McCarthy L; Guilcher SJT; Cadarette SM
Osteoporos Int; 2019 Sep; 30(9):1865-1872. PubMed ID: 31317248
[TBL] [Abstract][Full Text] [Related]
24. Long-term persistence in patients with osteoporosis receiving denosumab in routine practice: 36-month non-interventional, observational study.
Borek DM; Smith RC; Gruber CN; Gruber BL
Osteoporos Int; 2019 Jul; 30(7):1455-1464. PubMed ID: 31011760
[TBL] [Abstract][Full Text] [Related]
25. Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years.
Modi A; Sajjan S; Insinga R; Weaver J; Lewiecki EM; Harris ST
Osteoporos Int; 2017 Apr; 28(4):1355-1363. PubMed ID: 28058444
[TBL] [Abstract][Full Text] [Related]
26. Assessment of patient-reported outcomes (PROs): treatment satisfaction, medication adherence, and quality of life (QoL) and the associated factors in postmenopausal osteoporosis (PMO) patients in Korea.
Byun DW; Moon SH; Kim T; Lee HH; Park HM; Kang MI; Ha YC; Chung HY; Yoon BK; Kim TY; Chae SU; Shin CS; Yang KH; Lee JH; Chang JS; Kim SH; Kim IJ; Koh JM; Jung JH; Yi KW; Yoo JJ; Chung DJ; Lee YK; Yoon HK; Hong S; Kim DY; Baek KH; Kim HJ; Kim YJ; Kang S; Min YK
J Bone Miner Metab; 2019 May; 37(3):563-572. PubMed ID: 30238428
[TBL] [Abstract][Full Text] [Related]
27. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
Leder BZ; Tsai JN; Uihlein AV; Wallace PM; Lee H; Neer RM; Burnett-Bowie SA
Lancet; 2015 Sep; 386(9999):1147-55. PubMed ID: 26144908
[TBL] [Abstract][Full Text] [Related]
28. Medication persistence in older women with osteoporosis: a pilot study.
Gillette C; Howerton DM; Williams BD; Mahmood MA
Osteoporos Int; 2015 Dec; 26(12):2883-8. PubMed ID: 26194492
[TBL] [Abstract][Full Text] [Related]
29. Patterns of treatment among a cohort of older low-income adults starting new medications for osteoporosis.
Solomon DH; Brown EM; Chandler D; Bower A; Barron R; Mogun H; Franklin JM
Osteoporos Int; 2014 Sep; 25(9):2255-62. PubMed ID: 24899104
[TBL] [Abstract][Full Text] [Related]
30. Gastrointestinal symptoms and association with medication use patterns, adherence, treatment satisfaction, quality of life, and resource use in osteoporosis: baseline results of the MUSIC-OS study.
Modi A; Sen S; Adachi JD; Adami S; Cortet B; Cooper AL; Geusens P; Mellström D; Weaver J; van den Bergh JP; Nguyen AM; Sajjan S;
Osteoporos Int; 2016 Mar; 27(3):1227-1238. PubMed ID: 26637321
[TBL] [Abstract][Full Text] [Related]
31. Fear of falling, fracture history, and comorbidities are associated with health-related quality of life among European and US women with osteoporosis in a large international study.
Guillemin F; Martinez L; Calvert M; Cooper C; Ganiats T; Gitlin M; Horne R; Marciniak A; Pfeilschifter J; Shepherd S; Tosteson A; Wade S; Macarios D; Freemantle N
Osteoporos Int; 2013 Dec; 24(12):3001-10. PubMed ID: 23754200
[TBL] [Abstract][Full Text] [Related]
32. Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates.
Petranova T; Boyanov M; Shinkov A; Petkova R; Intorcia M; Psachoulia E
Arch Osteoporos; 2017 Dec; 13(1):1. PubMed ID: 29264666
[TBL] [Abstract][Full Text] [Related]
33. Patterns and predictors of osteoporosis medication discontinuation and switching among Medicare beneficiaries.
Yun H; Curtis JR; Guo L; Kilgore M; Muntner P; Saag K; Matthews R; Morrisey M; Wright NC; Becker DJ; Delzell E
BMC Musculoskelet Disord; 2014 Apr; 15():112. PubMed ID: 24684864
[TBL] [Abstract][Full Text] [Related]
34. Impact of bone turnover markers and/or educational information on persistence to oral bisphosphonate therapy: a community setting-based trial.
Silverman SL; Nasser K; Nattrass S; Drinkwater B
Osteoporos Int; 2012 Mar; 23(3):1069-74. PubMed ID: 21755401
[TBL] [Abstract][Full Text] [Related]
35. Bisphosphonate prescribing, persistence and cumulative exposure in Ontario, Canada.
Burden AM; Paterson JM; Solomon DH; Mamdani M; Juurlink DN; Cadarette SM
Osteoporos Int; 2012 Mar; 23(3):1075-82. PubMed ID: 21604008
[TBL] [Abstract][Full Text] [Related]
36. Improving adherence to and persistence with oral therapy of osteoporosis.
Bianchi ML; Duca P; Vai S; Guglielmi G; Viti R; Battista C; Scillitani A; Muscarella S; Luisetto G; Camozzi V; Nuti R; Caffarelli C; Gonnelli S; Albanese C; De Tullio V; Isaia G; D'Amelio P; Broggi F; Croci M
Osteoporos Int; 2015 May; 26(5):1629-38. PubMed ID: 25619634
[TBL] [Abstract][Full Text] [Related]
37. Marginal structural model to evaluate the association between cumulative osteoporosis medication and infection using claims data.
Xue F; Goli V; Petraro P; McMullan T; Sprafka JM; Tchetgen Tchetgen EJ
Osteoporos Int; 2017 Oct; 28(10):2893-2901. PubMed ID: 28685279
[TBL] [Abstract][Full Text] [Related]
38. Persistence with denosumab therapy in women affected by osteoporosis with fragility fractures: a multicenter observational real practice study in Italy.
Migliaccio S; Francomano D; Romagnoli E; Marocco C; Fornari R; Resmini G; Buffa A; Di Pietro G; Corvaglia S; Gimigliano F; Moretti A; de Sire A; Malavolta N; Lenzi A; Greco EA; Iolascon G
J Endocrinol Invest; 2017 Dec; 40(12):1321-1326. PubMed ID: 28589380
[TBL] [Abstract][Full Text] [Related]
39. Adherence and persistence in patients with severe osteoporosis treated with teriparatide.
Ziller V; Zimmermann SP; Kalder M; Ziller M; Seker-Pektas B; Hellmeyer L; Hadji P
Curr Med Res Opin; 2010 Mar; 26(3):675-81. PubMed ID: 20078188
[TBL] [Abstract][Full Text] [Related]
40. Physician perception of patient adherence compared to patient adherence of osteoporosis medications from pharmacy claims.
Copher R; Buzinec P; Zarotsky V; Kazis L; Iqbal SU; Macarios D
Curr Med Res Opin; 2010 Apr; 26(4):777-85. PubMed ID: 20095797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
